Technical advancement in regulatory T cell isolation and characterization using CD127 expression in patients with malignant glioma treated with autologous dendritic cell vaccination
/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2009-10-27 / J. Immunol. Methods 2010 Jan;352(1-2):169-73Dendritic cell therapy of high-grade gliomas
/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2009-10-01 / Brain Pathol. 2009 Oct;19(4):694-712Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2009-09-01 / J BUON 2009 Sep;14 Suppl 1:S111-22Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2009-06-10 / J. Virol. 2009 Aug;83(16):8108-21Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):971-82Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):951-62Vaccine therapy in patients with renal cell carcinoma
/in Hypernephroma, International Publications, IOZK Veröffentlichungen /von 2009-01-30 / Eur. Urol. 2009 Jun;55(6):1333-42Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2009-01-01 / Methods Mol. Biol. 2009;542:565-605Randomized clinical studies of anti-tumor vaccination: state of the art in 2008
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen /von 2009-01-01 / Expert Rev Vaccines 2009 Jan;8(1):51-66
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de